Common Warts
Verrica has announced positive top-line results from its COVE-1 Phase 2 open-label clinical trial of VP-102 for the treatment of verruca vulgaris, or common warts. The study included two cohorts that evaluated the safety and efficacy of VP-102 in patients with up to six warts. In both cohorts, VP-102 achieved positive results on both the primary endpoint of percentage of subjects with complete clearance of all treatable warts and the secondary endpoint of the percentage of reduction of warts from baseline.
Verrica is planning a Phase 3 program to further evaluate VP-102 for the treatment of common warts.
Basel Cell Carcinoma
Verrica has announced top-line results from a Phase 2 trial of VP-315 in BCC. The Phase 2 trial was a two-part, open-label, multicenter, dose-escalation, proof-of-concept trial of VP-315 when administered intratumorally to adults with biopsy-proven BCC. Part 1 of the trial was designed to evaluate VP-315’s safety profile when administered in escalating doses to individual subjects. Part 2 was designed to confirm the exploratory dose from Part 1 and determine the optimal therapeutic regimen.
Verrica is planning a Phase 3 program to further evaluate VP-315 for the treatment of BCC.
